Results 51 to 60 of about 145,387 (305)

Dynamics and Radiation of Young Type-Ia Supernova Remnants: Important Physical Processes

, 2004
We examine and analyze the physical processes that should be taken into account when modeling young type-Ia SNRs, with ages of several hundred years. It is shown, that energy losses in the metal-rich ejecta can be essential for remnants already at this ...
A. D. Whiteford, A. Decourchelle, A. J. S. Hamilton, A. J. S. Hamilton, A. V. Borovskii, C. Badenes, C. E. Max, C. F. McKee, C. P. Ballance, C. W. Gear, D. A. Verner, D. A. Verner, D. H. Sampson, D. I. Kosenko, D. K. Nadezhin, E. I. Sorokina, H. Itoh, H. L. Zhang, H. Lesch, H. Nussbaumer, H. Regemorter van, J. M. Laming, K. A. Arnaud, K. J. Borkowski, K. Nomoto, L. A. Vainshtein, L. Spitzer, M. Arnaud, M. J. Seaton, M. J. Shull, M. Reinecke, N. A. Bobrova, N. V. Dunina-Barkovskaya, O. B. Arushanyan, P. J. Cargill, P. Lundqvist, R. A. Chevalier, R. S. Cohen, S. A. Maiorov, S. I. Blinnikov, S. I. Blinnikov, S. I. Blinnikov, S. J. Goett, U. Hwang, V. S. Imshennik, V. S. Imshennik, W. Brinkmann   +46 more
core   +1 more source

Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya, Veronica Moroz, Juliet Hale, Vesna Pavasovic, Rachel Hobson, Patricia Sartori, Daniel Saunders, Mark Powis, Gordan M. Vujanic, Stephen Baker, Kathy Pritchard‐Jones   +10 more
wiley   +1 more source

A High-Voltage Low-Power Switched-Capacitor DC-DC Converter Based on GaN and SiC Devices for LED Drivers

Elektronika ir Elektrotechnika, 2018
Previous research on switched-capacitor DC-DC converters has focused on low-voltage and/or high-power ranges, where the efficiencies are dominated by conduction losses.
Lin Fan, Arnold Knott, Ivan Harald Holger Jorgensen   +2 more
doaj   +1 more source

An Analytical Model of Dynamic Power Losses in eGaN HEMT Power Devices

Micromachines, 2023
In this work, we present an analytical model of dynamic power losses for enhancement-mode AlGaN/GaN high-electron-mobility transistor power devices (eGaN HEMTs). To build this new model, the dynamic on-resistance (Rdson) is first accurately extracted via
Jianming Lei, Yangyi Liu, Zhanmin Yang, Yalin Chen, Dunjun Chen, Liang Xu, Jing Yu   +6 more
doaj   +1 more source

Exploring Preferences for a Digital Single‐Session Intervention for Adolescent Siblings of Youth With Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Adolescent siblings of children with cancer are at elevated risk for psychosocial problems. Unfortunately, various barriers such as limited family time and resources, conflicting schedules, and psychosocial staffing constraints at cancer centers hinder sibling access to support.
Christina M. Amaro, Sarah Silver, Prishi Patel, Meredith K. Reffner Collins, Kimberly S. Canter, Stephanie Fooks‐Parker, Michael Amylon, Shawna V. Hudson, Jessica L. Schleider, Melissa A. Alderfer, Katie A. Devine   +10 more
wiley   +1 more source

Concept of Enabling Over-Current Capability of Silicon-Carbide-Based Power Converters with Gate Voltage Augmentation

Energies
Various methods have been discussed in the literature regarding enabling the over-current (OC) capability of silicon carbide (SiC) MOSFETs. SiC MOSFETs can operate at up to 250 °C without failure. One of their features is to permit transient operation at
Shubhangi Bhadoria, Qianwen Xu, Xiongfei Wang, Hans-Peter Nee   +3 more
doaj   +1 more source

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

A ZVT–ZCT PWM synchronous buck converter with a simple passive auxiliary circuit for reduction of losses and efficiency enhancement

Ain Shams Engineering Journal, 2015
In this paper, a Zero-Voltage-Transition (ZVT)–Zero-Current Transition (ZCT) Pulse-width Modulated (PWM) synchronous buck converter (SBC), with a simple passive auxiliary circuit is proposed, which reduces the stresses and improves the efficiency by ...
S. Shiva Kumar, A.K. Panda, Tejavathu Ramesh   +2 more
doaj   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

Issues Concerning the Mechanisms of Bone Conduction

Audiology Research
Air and bone conduction thresholds are used to differentiate between conductive and sensori-neural hearing losses because bone conduction is thought to bypass the conductive apparatus, directly activating the inner ear.
Miriam Geal-Dor, Cahtia Adelman, Haim Sohmer   +2 more
doaj   +1 more source